देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
TOPIRAMATE
GLENMARK PHARMACEUTICALS CANADA INC.
N03AX11
TOPIRAMATE
100MG
TABLET
TOPIRAMATE 100MG
ORAL
100
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0132938002; AHFS:
APPROVED
2014-09-02
_Pr_ _GLN-TOPIRAMATE (Topiramate Tablets) _ _ _ _Page 1 of 76 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR GLN-TOPIRAMATE Topiramate Tablets Tablets, 25 mg, 100 mg, and 200 mg, Oral USP Antiepileptic / Migraine Prophylaxis Glenmark Pharmaceuticals Canada Inc. 1600 Steeles Ave. West, Suite 407 Concord, Ontario L4K 4M2 Date of Initial Authorization: November 03, 2006 Date of Revision: January 23, 2024 Submission Control Number: 278404 _Pr_ _GLN-TOPIRAMATE (Topiramate Tablets) _ _ _ _Page 2 of 76 _ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, OPHTHALMOLOGIC 01/2023 7 WARNINGS AND PRECAUTIONS, REPRODUCTIVE HEALTH: FEMALE AND MALE POTENTIAL, TERATOGENIC RISK 01/2024 7 WARNINGS AND PRECAUTIONS, INFORMATION FOR PATIENTS, FETAL TOXICITY 01/2024 7.1.1 PREGNANT WOMEN 01/2024 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. _ _ RECENT MAJOR LABEL CHANGES ......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................. 4 1 INDICATIONS ........................................................................................................................... 4 1.1 Pediatrics ........................................................................................................................... 4 1.2 Geriatrics ........................................................................................................................... 4 2 CONTRAINDICATIONS ............................................................................................................ 4 4 DOSAGE AND ADMINISTRATION .......................................................................................... 5 4.1 Dosing Considerations ..................................................................... पूरा दस्तावेज़ पढ़ें